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Background: Intermittent treatment with TKIs is an option for the great majority 
(70%– 80%) of CML patients who do not achieve a stable deep molecular response 
and are not eligible for treatment discontinuation. For these patients, the only alterna-
tive is to assume TKI continuously, lifelong.
Methods: The Italian phase III multicentric randomized OPTkIMA study started in 
2015, with the aim to evaluate if a progressive de- escalation of TKIs (imatinib, nilo-
tinib, and dasatinib) is able to maintain the molecular response (MR3.0) and to im-
prove Health Related Quality of Life (HRQoL).
Results: Up to December 2018, 166/185 (90%) elderly CML patients in stable MR3.0/
MR4.0 completed the first year of any TKI intermittent schedule 1 month ON and 
1 month OFF. The first year probability of maintaining the MR3.0 was 81% and 23.5% 
of the patients who lost the molecular response regained the MR3.0 after resuming TKI 
continuously. Patients’ HRQoL at baseline was better than that of matched peers from 
healthy population. Women was the only factor independently associated with worse 
baseline HRQoL (p > 0.0001). Overall, global HRQoL worsened at 6 (p < 0.001) but 
returned to the baseline value at 12 months and it was statistically significantly worse 
in women (p = 0.001).
Conclusions: De- escalation of any TKI by 1 month ON/OFF schedule maintains the 
MR3.0/MR4.0 in 81% of the patients during the first 12– 24 months. No patients pro-
gressed to accelerated/blastic phase, all the patients (23.5%) losing MR3.0 regained 
the MR3.0 and none suffered from TKI withdrawn syndrome. The study firstly report 
on HRQoL in elderly CML patients moving from a continuous daily therapy to a de- 
escalated intermittent treatment.
K E Y W O R D S
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1 |  INTRODUCTION
Tyrosine Kinase Inhibitors (TKIs) significantly improved 
the life expectancy of patients with Philadelphia- positive 
Chronic Myeloid Leukaemia (CML).1- 3
The current treatment strategy with TKIs aims to prevent 
CML progression to accelerated/blastic phase (AP/BP) and 
to access drug discontinuation and treatment- free remis-
sion (TFR). Molecular response (≤0.1% BCR- ABL1%IS) is 
achieved in 80– 90% of patients and 30– 50% of them obtain 
deep molecular response (DMR) (≥MR4.0  ≤0.01% BCR- 
ABL1%IS or 10.000 copies of transcript as minimum sum of 
reference gene). Patients in stable DMR have access to TFR, 
but, invariably, half of them loses molecular response with 
need of restarting treatment.4
Although no more than 20%– 25% of the whole CML 
patients population can get and maintain the TFR,5 TKIs 
discontinuation has become the current paradigm of CML 
management and TFR the main goal of TKI therapy.6- 9
This current approach, nowadays recommended,10,11 is far 
from being optimal and, in absence of concrete strategies to 
increase the number of deep molecular responders, it makes 
approximately 80% of the patients to have no alternative but 
to continue the daily treatment lifelong.6,12- 14
For these latter patients, this expectation raises a num-
ber of important questions concerning the adherence and 
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tolerance to therapy, including the late and unexpected side 
effects, the quality of life, and the sustainable costs of ther-
apy. These questions are particularly relevant in the CML el-
derly population, in whom these issues are likely to be not 
only dose dependent but also age related.15
Furthermore, these questions are also clinically and so-
cially relevant because it is known that the incidence of CML 
progresses with age and, in the next years, the prevalence of 
CML in elderly population is expected to increase.16- 19
The previous phase II INTERIM study20 demonstrated that 
a policy of intermittent imatinib treatment (1 month ON– one 
month OFF) in elderly CML patients is feasible and successful, 
at long term. After 6 years of follow up, neither progression to 
blastic phase nor CML- related deaths were recorded, the pa-
tients who had lost the complete cytogenetic response (CCyR) 
regained the CCyR after resuming imatinib continuously and 
60% are on intermittent treatment in CCyR and MR3.0 or 
MR4.0.21 Furthermore, grade I- II side effects disappeared in 
more than 50% of the patients on intermittent treatment.
The European Forum for Good Clinical Practice (EFGCP) 
pointed out the need to increase participation of elderly peo-
ple in clinical trials, particularly in the case of patients with 
hematologic malignancies, where health- related quality of 
life (HRQoL) issues have been understudied.22 Since little 
data exist on the effect of TKIs on quality of life in CML 
patients,23,24 new specific clinical trials, which also include 
HRQoL, may provide the lacking information in elderly 
CML patients.
To this purpose, in July 2015, an Italian prospective multi-
centric randomized phase III trial was started with the aim to 
validate the policy of the intermittent de- escalation treatment 
and to explore the impact of this strategy on the HRQoL. In 
this first interim report, we focused on the patients who, by 
intention to treat, have completed the first year of the study, 
to achieve information on maintenance of MR3.0/MR4.0 mo-
lecular response and also HRQoL.
2 |  PATIENTS AND METHODS
2.1 | OPTkIMA study design
OPTkIMA study is an ongoing Italian phase III multi-
centric randomized study, where a “fixed” intermittent 
administration (1  month ON/OFF) of TKI (control arm), 
the same of the previous INTERIM Study, is compared 
with a “progressive” intermittent administration (1 month 
ON– 1 month OFF for the 1st year; 1 month ON– 2 months 
OFF for the 2nd year; and 1  month ON– 3  months OFF 
for the 3rd year) (experimental arm). The study was ap-
proved by the local Ethical Committees of all the partici-
pating Centers, and was registered at ClinicalTrials.gov 
(NCT02326311).
Upon signing of written informed consent, chronic- phase 
(CP) Ph+ CML patients older than 60 years and in MR3.0 or 
MR4.0 after ≥2 years of daily treatment with imatinib (IM), 
nilotinib (NIL), or dasatinib (DAS) have been randomized 
1:1 to receive “fixed” or “progressive” intermittent admin-
istration. Randomization has been stratified by type of TKI 
(IM, NIL, or DAS) and by depth of molecular response 
(MR3.0 or MR4.0), according to the IS, as recommended by 
the International Experts Panel's Guide Lines.21 IM, NIL, or 
DAS have been administered intermittently at the same daily 
dose given at the time of the enrollment.
The study aims to validate “fixed” intermittent administration 
(1 month ON/OFF) of TKI, previously explored in the INTERIM 
Trial,21 and to evaluate if a “progressive” increase in intermit-
tent treatment discontinuation until 3 months is able to maintain 
the MR3.0 / MR4.0 molecular response and improve HRQoL 
outcomes. Patients’ self- reported European Organization for 
Research and Treatment of Cancer (EORTC) outcome measures 
have been assessed throughout the 3 years follow- up period.
Molecular monitoring was performed according to the 
2013 ELN guidelines every 3 months by RT- qPCR on periph-
eral blood.25 In case of MR3.0 loss, checked in two monthly 
consecutive RT- qPCR analysis, patients were planned to re-
sume TKI daily and continued to be followed.
2.2 | Definition of molecular response
RT- qPCR assessments were carried out at the Reference 
Laboratory of each participating Center, according to ELN 
Guidelines. At each time point scheduled for the MRD moni-
toring, 10 ml of peripheral blood was sampled for RT- qPCR 
analysis. Molecular response (MR) by RT- qPCR was defined 
according to the latest laboratory recommendations and using 
ABL1 as reference gene. Measurable MR was assigned fol-
lowing the international scale (IS) and scored MR3.0 if ≤0.1% 
BCR- ABL1%IS, MR4.0 if ≤0.01% BCR- ABL1%IS, MR4.5 
if ≤0.0032% BCR- ABL1%IS, and MR5.0 if ≤0.001 BCR- 
ABL1%IS. Minimum sum of ABL1 reference gene transcripts, 
irrespective of whether BCR- ABL1 was detected or not, 10.000, 
32.000, and 100.000 for MR4.0, MR4.5, and MR5.0, respectively. 
The participating Reference Labs belonged to the Gruppo 
Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Labnet 
and accredited by the GIMEMA Labnet Quality Committee to 
release the results of RT- qPCR analysis, since certified for the 
quantification of BCR- ABL1 according to the IS, as recom-
mended by the International Experts Panel's Guide Lines.26
2.3 | Procedures for HRQoL assessment
Health- related quality of life (HRQoL) was assessed with 
the EORTC Quality of Life Questionnaire- Core 30 (EORTC 
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QLQ- C30)27 and its QLQ- CML24 28 and the QLQ- ELD- 14 
29 modules. During the first year (i.e., when treatment sched-
ule between arms was not different, 1 month ON/OFF), the 
protocol stipulated that HRQoL had to be assessed at base-
line and then at 3, 6, and at 12 months. Afterwards, HRQoL 
was assessed at 18, 24, 30, and 36  months and these time 
points were chosen to maximize the sensitivity to possible 
effects of treatments being tested.
2.4 | Statistical analysis
The HRQoL compliance for each time point was calculated as 
the percentage of returned questionnaires out of those expected 
from patients still on study. Proportions, means, standard devia-
tion, and medians were used to summarize patients’ character-
istics. We used uni- and multivariable linear regression analysis 
to estimate the association of baseline global health status/QoL 
with key sociodemographic and clinical factors such as age, gen-
der, comorbidities (at least two vs. one or less), type of TKI (first 
vs. second generation), and the duration of therapy with TKIs 
at study entry (months). We also used a linear mixed model for 
repeated measures to estimate mean HRQoL trajectories over 
time, testing the null hypothesis of no change from baseline by 
an overall F- test. We used the same approach to estimate the 
mean HRQoL trajectories by sex, testing the null hypothesis of 
no difference between men and women. For descriptive pur-
poses, we also assessed the prevalence of clinically important 
problems and symptoms by gender, as defined as in previously 
published work.30 All statistical tests were two- sided, with statis-
tical significance set as α = 0.05. Due to the exploratory nature 
of the analyses, we did not adjust for multiple testing.
3 |  RESULTS
3.1 | Interim report
In this first interim report, the patients who, by intention to 
treat, have completed the first year of the study were evalu-
ated. Since the treatment intermittent schedule is not dif-
ferent during the 1st year of therapy for both the patients 
randomized in the “fixed” and in the “progressive” arms, it is 
expected that no differences will be found up to the end of the 
1st year in the two arms, but information on loosing of MR3.0/
MR4.0 molecular response and HRQoL can be obtained.
3.2 | Treatment and molecular results
Up to December 2018, 185 patients have been enrolled by 
26 Italian Hematological Centers (first patient randomized 
in July 2015) and 166/185 patients (90%) completed the first 
year of follow up in the OPTkIMA study. Table 1 reports the 
most important clinical and biological characteristics of the 
185 patients. The median age was 71  years (range 60– 89) 
and 61% of the patients belonged to the Sokal intermediate- /
high- risk group. A total of 140/185 (76%), 25/185 (13%), and 
20/185 (11%) patients were receiving IM, NIL, and DAS, at 
the time of enrollment, respectively. Overall, 99/185 (54%) 
and 86/185 (46%) patients have been randomized in the 
“fixed” and “progressive” arms, respectively.
A total of 47/166 patients (28%) abandoned the intermittent 
treatment during the 1st year. The reasons of intermittent sched-
ule discontinuation were as follows: informed consent with-
drawn (4/166– 2%), second cancer (4/166– 2%), and loss of MR3.0 
(39/166– 23.5%) (Table 2). No patient progressed to AP/BP.
Considering these last 39 patients who lost MR3.0 in the 
1st year, 22 and 17 were in MR4.0 and MR3.0 when they were 
enrolled into the study, respectively. Thus, the probability of 
maintaining the MR3.0 while on OPTkIMA was 81% at 1 year 
(95% CI 0.75– 0.87) (Figure 1). Moreover, of the 166 patients 
who completed the first year of OPTkIMA, 136 (82%) and 30 
(18%) were in MR4.0 and MR3.0 at baseline, respectively. As a 
consequence, 22/136 (16%) and 17/30 (57%) patients in MR4.0 
and MR3.0 at baseline lost the molecular response during the 
1st year (p < 0.00001). The impact of the most important clin-
ical and biological variables (age, gender, disease risk accord-
ing to Sokal, EURO, and EUTOS score, time from diagnosis 
to enrollment, type of BCR- ABL transcript, dose of TKI, du-
ration of TKI, depth of molecular response, and duration of 
MR3.0) on the probability to maintain the MR3.0 was analyzed 
by univariate analysis. The only factor associated with a higher 
probability to maintain the MR3.0 was a duration of MR3.0 
greater than 3 years [HR 0.23, 95%CI 0.10– 0.61), p = 0.0025] 
(Table 3). All the 39 patients resumed the same TKI continu-
ously and all but 2 (95%) obtained at least the MR3.0 response, 
within 6 months. The mutational analysis was performed by 
denaturing high- performance liquid cromatography (DHPLC) 
in all the cases and in 2/39 patients (5%) an ABL mutation was 
detected (D363Y and Y320C). Both of these 2 patients did 
not re- achieve the MR3.0 with imatinib: one shifted to nilotinib 
after 3 months and is currently in follow up; the other one died 
for progressive rheumatologic disease not in MR3.0.
3.3 | Treatment and tolerance
The adverse events registered in the electronic CRFs and 
managed according to the published ELN guidelines31 are 
reported in Table 4. Overall, the intermittent treatment was 
well tolerated, with 6 serious adverse events (2 appendicitis, 
1 peri- anal abscess, 1 heart- failure, 1 hip fracture, and 1 se-
vere artheriopathy) and 27 nonsevere adverse, of which 13 
were reported in the first 9 months of the study time and 14 at 
the 12th month. None of these events were treatment related. 
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According to the data reported in the electronic CRFs, none 
of the patients experienced the TKI withdrawn syndrome.
3.4 | Update beyond the 1st year
After the 1st year of intermittent treatment (1  month ON/
OFF), 119 patients entered the 2nd year, of whom 63 (54%) 
and 56 (47%) belonged to the “fixed “and “progressive” arm, 
respectively. Overall, 105/119 patients (88%) completed the 
2nd year, of whom 59 (56%) in the “fixed” and 46 (44%) in 
the “progressive” arm.
Of 63 patients randomized to the “fixed” arm who entered 
the 2nd year, 4 (6%) discontinued the intermittent schedule 
because of death for second cancer (2 cases) and senectus (2 







(n = 86 – 46%) p
M/F 106/79 (57% / 43%) 51/48 (52% - 48%) 55/31 (64% - 36%) 0.10
Median age (range) 71 (60– 89) 70 (60– 89) 72.5 (60– 85) 0.02
Type of transcript 185 99 85 0.24
b3a2 121 (65%) 61 (62%) 59 (69%)
b2a2 64 (35%) 38 (38%) 26 (31%)
Sokal 0.09
L 73 (40%) 37 (37%) 36 (42) 0.09
I 82 (44%) 42 (42%) 41 (48%)





























Median duration of 
TKI (mo)
87.5 (24– 245) 85 (24– 245) 90 (24– 194) 0.79
Molecular response at 
enrollment
0.48
MR3.0 37 (20%) 18 (18%) 19 (22%)
MR4.0 146 (79%) 78 (79%) 67 (78%)
> MR4.0 2 (1%) 2 (2%) 0 (0%)
Pts with at least 2 
comorbidities
121 (65%) 58 (58%) 63 (73%) 0.07
Pts with at least 2 drugs 
other than TKI
117 (63%) 60 (61%) 57 (66%) 0.10
L = Sokal Low risk; I = Sokal Intermediate risk; H = Sokal High risk; IMA = imatinib; NILO = nilotinib; 
DAS = dasatinib.
T A B L E  1  Clinical and biological 
characteristics of the 185 patients enrolled in 
OPTkIMA trial
TOT IC withdrawn Second Cancer Loss of MR3.0
3°Month 14 3 1 10
6°Month 21 1 1 19
9°Month 4 0 1 3
12°Month 8 0 1 7
TOT 47/166 (28%) 4/166 (2%) 4/166 (2%) 39a /166 (23%)
a At the time of enrollment: 17 in MR3.0 and 22 in MR4.0. 
T A B L E  2  Patients and causes of 
OPTkIMA discontinuation in the 1st year 
of intermittent treatment 1 month ON and 
1 month OFF
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F I G U R E  1  Probability of maintaining 
MR3.0 at 1st year of OPTkIMA
T A B L E  3  Forest plot analysis on the impact of the clinical and biological variables on the probability of MR3.0 loss— Univariate analysis
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3.5 | Health- related quality of Life 
(HRQoL) results
3.5.1 | Compliance and baseline QoL Profile
Compliance with HRQoL questionnaires was as follows: 
96%, 91%, 92%, and 80% at baseline, 3, 6, and 12 months, re-
spectively. As reported in Figure 2, baseline symptoms pro-
file of OPTkIMA patients generally showed better reported 
symptoms with respect to gender- and age- matched peers 
from the general population.32,33 Female gender was the only 
factor independently associated with worse baseline HRQoL 
in multivariable analysis (p  <.0001), while controlling for 
other key potential confounding factors, including age, num-
ber of comorbidities, type of TKI, and duration of previous 
treatment (Table  5). The prevalence of clinically relevant 
problems was higher in female patients across all EORTC 
QLQ- C30 scales with the largest difference found for physi-
cal functioning, being 36.6% and 62% for male and female 
patients, respectively. Details are reported in Figure 3.30
3.5.2 | Longitudinal QoL profile
Statistically significant improvements over time were found 
for diarrhea at 6 (p  =  0.022) and 12  months (p  =  0.022), 
with mean score decreasing from 11.5 points at baseline to 
5.4 points at 12 months. These changes were also clinically 
meaningful across all time points (Figure  4). Nausea and 
vomiting scale also improved at 3  months (p  =0.006) and 
then returned to baseline levels (Figure 4). There was a stati-
cally significant worsening in fatigue severity at 6 (p = 0.001) 
and 12 months (p = 0.022) (Figure 4). Global HRQoL also 
decreased at 6 months (p < 0.001) but then returned to base-
line levels at 12 months (Figure 4). However, global HRQoL 
over time was statically significantly different (p = 0.001) by 
gender with female patients reporting worse outcomes during 
the 12 months of observation (Figure 5). No other scales of 
the EORTC QLQ- C30 showed a statistically significant dif-
ference from baseline at any time point.
4 |  DISCUSSION
OPTkIMA Study is a phase III Italian randomized trial, 
started in July 2015, where elderly (≥60 years) CML patients 
in stable molecular response (MR3.0 or MR4.0) after ≥2 years 
of standard treatment with IM, NIL, or DAS are randomized 
1:1 to receive “fixed” or “progressive” intermittent TKI ad-
ministration until MR3.0 is lost.
The main objectives of the study are to assess the chang-
ing of HRQoL in the patients moving from a continuous to 
a progressive de- escalated intermittent TKIs treatment and 
to find the TKI minimum effective dose able to maintain the 
major molecular response (MR3.0).
It is known that persistent or recurrent low- grade adverse 
events (AEs) are common in CML patients during chronic 
treatment with TKIs. These events alter the patient's HRQoL 
and adherence to therapy and may cause lifelong comorbidi-
ties, especially in the elderly.
This first interim analysis was made to acquire informa-
tion on HRQoL and on the maintenance of MR3.0/MR4.0 in 
those patients of the both arms who received IM, NIL, or 
DAS “one month ON/OFF” for the 1st year.




Artheriopathy Yes 1st ON
Heart failure Yes 2nd OFF
Appendicitis Yes 4th OFF
Appendicitis Yes 11th ON
Hip fracture Yes 11th ON
Peri- anal abscess Yes 12th OFF
Ascites No 1st ON
Arthritis No 2nd OFF
Chills No 2nd OFF
Cramps No 3rd ON
Hand pain No 3rd ON
Chills No 5th ON
Legs edema No 6th OFF
Atrial Fibrillation No 6th OFF
Inguinal Hernia No 7th ON
Conjunctiva bleeding No 9th ON
Hypotension No 9th ON
Dyspnea No 9th ON
Arthritis No 9th ON
Pneumonia No 10th OFF
Peri- orbital edema No 10th OFF
Bronchitis No 10th OFF
Diarrhea No 11th ON
Influenza No 12th OFF
Fever No 12th OFF
Itch No 12th OFF
Fever No 12th OFF
Drowsiness No 12th OFF
Fever No 12th OFF
Post- vitreous detachment No 12th OFF
Diarrohes No 12th OFF
Cramps No 12th OFF
Hypertension No 12th OFF
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Although patients’ accrual was lower than expected, the 
compliance in reporting the HRQoL questionnaires was ex-
tremely satisfying (more than 90% in the first 6 months and 
80% at the 12th month). Analyzing the HRQoL, the baseline 
profile of OPTkIMA patients was better than that of gender- 
and age- matched healthy participants (Figure  2).32,33 We 
were surprised of that, and even more by the fact that female 
was the only factor independently associated with worse base-
line HRQoL in multivariable analysis (p < 0.0001) (Table 2).
Concerning these findings, we can speculate that elderly 
patients with CML who are in stable molecular response 
have a good HRQoL, being confident with their disease, and 
considering themselves as cancer Survivors could tend to 
minimize some symptoms associated with aging, that, on the 
contrary, patients without cancer may consider as important 
and detrimental for HRQoL. In the second case, the preva-
lence of clinically relevant symptoms was higher in women 
(62%) than in men (36.6%), and the largest difference was 
found in the physical functioning (Figure 3).
Other hematologic and oncologic studies investigating the 
HRQoL report a worst HRQoL in the female with respect to 
the male gender,34 and different factors have been discussed 
as possible causes. The modern society strongly leans on el-
derly women more than elderly men (e.g., daily management 
of the family, housekeeping, grandchildren management, 
etc.). As a consequence, a cancer diagnosis, its treatment, as 
well as the participation in a clinical trial, such as OPTkIMA, 
may impair the physical and mental functioning of an elderly 
F I G U R E  2  Baseline symptom profile of OPTkIMA patients versus sex and age matched peers from general population. Legend: * = clinically 
meaningful difference. The figure represents the age- sex adjusted mean level of symptom burden per group
Variables
Univariate analysis Multivariate analysis
Estimate (95% CI) p- value Estimate (95% CI) p- value
Age (y) −0.28 (−0.70; 0.14) 0.192 −0.23 (−0.63; 0.18) 0.273
Being female −11.96 (−17.82; −6.11) <0.0001 −12.51 (−18.32; −6.70) <0.0001
At least 2 
comorbidities
−5.16 (−11.24; 0.92) 0.096 −5.28 (−11.17; 0.61) 0.079
2nd- generation TKIa −2.20 (−9.40; 5.01) 0.548 −0.31 (−7.33; 6.7) 0.930
TKI duration 
(months)
0.07 (0.01; 0.13) 0.036 0.06 (0.00; 0.13) 0.062
The bold values represent the significant parameters associated with global HRQoL.
a Nilotinib or dasatinib (reference category is the first- generation TKI imatinib). CI, confidence interval. 
T A B L E  5  Multivariable regression 
analysis of baseline Global Quality of Life 
(EORTC QLQ- C30)
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female patient more significantly than those of elderly male 
patient.
Monitoring the symptoms, a statistically significant im-
provement over time was found for diarrhea at 6 (p = 0.022) 
and 12 months (p = 0.022) (Figure 4). For other symptoms, 
such as nausea and vomiting, the scale also improved at 
3  months (p  =  0.006) and then returned to baseline levels 
(Figure 4). On the contrary, there was a statically significant 
worsening in fatigue severity at 6 (p = 0.001) and 12 months 
(p = 0.022) (Figure 4).
Global HRQoL also decreased at 6 months (p < 0.001) 
but then returned to baseline levels at 12 months (Figure 4).). 
Once again, when the global HRQoL over time was evalu-
ated, it was statistically significantly different (p = 0.001) by 
gender with female patients reporting worse outcomes during 
the 12 months of observation (Figure 5).
The interpretation of these data is indeed difficult and in-
triguing. The amelioration of symptoms such as diarrhea or 
nausea can be related to the intermittent TKI administration 
that, particularly in the first months after its initiation, can 
significantly reduce symptoms associated with the continu-
ous long- lasting TKI administration (notably the median du-
ration of continuous TKI administration ranges between 85 
and 90 months in our patients).
F I G U R E  3  Prevalence of clinically important problems and symptoms by gender. (A) Functional scales, (B) Symptom scales. Legend: 
Clinically important problems and symptoms (Giesinger et al. J Clin Epidemiol. 2019 Oct 19;118:1– 8)
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The worsening in the fatigue scale at 6th and 12th month 
and the decrease in the global HRQoL at 6th month could be in-
duced by the stress in patients who are normally well confident 
with their disease, its control, and its remission. Furthermore, 
even though no physician reported in the electronic CRF the 
typical TKI withdrawn syndrome, it is possible that some mild 
symptoms associated with the month OFF may have affected 
the patient's reported outcome. However, we did not observe 
any significant reduction in hemoglobin level and none of the 
patients retired consent, suggesting that this lack of “improve-
ment” in HRQol was not significantly deemed by patients.
From the hematologic point of view, our analysis con-
firmed that the intermittent therapy is effective and safe. 
During the 1st year, 39/166 patients (23.5%) lost MR3.0 and 
all of them re- gained the major molecular response within 
6  months from resumption of continuous treatment. The 
probability of MR3.0 maintenance while on OPTkIMA at 
1 year was 81% (95% CI 0.75– 0.87; Figure 1), quite compa-
rable with the 80% MR3.0 maintenance at 1 year observed in 
the previous INTERIM trial.20,21
F I G U R E  4  Trajectories of change in quality of life outcomes for selected EORTC QLQ- C30 scales. Legend: For the global QoL scale higher 
scores indicate better QoL outcomes, whereas lower scores indicate worse QoL outcomes. For diarrhoea, fatigue, and nausea/vomiting higher 
scores indicate higher symptom severity, whereas lower scores indicate lower symptom severity. P- values refer to change from baseline
F I G U R E  5  Trajectories of gender differences in Global Quality of 
Life up to 12 months
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Of note, the depth of MR at baseline (MR3.0 and MR4.0) 
had an impact on the probability to maintain the MR while 
on intermittent schedule. Focusing on the 166 patients who 
completed the 1st year, 30 and 136 were in MR3.0 and MR4.0 
at baseline; 17/30 (57%) and 22/136 (16%) lost the molecu-
lar response during the 1st year, respectively (p < 0.00001). 
The only factor associated with a higher probability to 
maintain the MR3.0 by univariate analysis was a duration 
of MR3.0 greater than 3 years [HR 0.23, 95%CI 0.10– 0.61), 
p = 0.0025] (Table 3). The study is ongoing, and after the 1st 
year of intermittent treatment (1 month ON/OFF), 119 pa-
tients entered the 2nd year, 63 in the “fixed”, and 56 in the 
“progressive” arm, respectively, and none of them lost the 
MR3.0. Only another study explored a policy of TKI dose re-
duction. It is the DESTINY trial, in which a 50% daily dose 
reduction of IM in the first year followed by discontinuation 
of TKI was adopted [DESTINY trial 35]. Although DESTINY 
and OPTkIMA trials seem similar, they have substantial dif-
ferences. OPTkIMA trial includes elderly patients and is not 
aimed to treatment permanent discontinuation, but is planned 
to identify the minimum effective dose of TKI (IM, NIL, 
and DAS) able to maintain the MR3.0, which is a surrogate 
marker of survival. DESTINY trial enrolled younger patients 
and a 50% dose de- escalation for 12 months is scheduled as 
a bridge to IM discontinuation. This “clinical” selection may 
be improved by monitoring strictly the slope of the MR and 
by selecting for TD those patients with a MR slope showing 
a stability of BCR- ABL1 transcript levels.36
In conclusion, this first interim analysis showed that the 
intermittent therapy, 1 month ON/OFF, is equally effective 
and safe across all the three TKIs. It also allowed to acquire 
basal and relevant information on HRQoL in elderly CML 
patients moving from standard daily therapy to experimental 
intermittent treatment. Significant differences in the HRQoL 
were observed in comparison with healthy peers matched 
for gender and age and between men and women. The study 
is ongoing and relevant information on the comparison of 
HRQoL between the “fixed” and the “progressive” random-
ization arms will be available in the next future.
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